Source: https://patents.google.com/patent/USRE39221
Timestamp: 2019-07-17 17:51:07
Document Index: 791004028

Matched Legal Cases: ['art 1', 'art 2', '§ 102', '§ 102', '§ 102', '§ 102', 'art 1', 'art 2']

USRE39221E1 - Composition comprising a tramadol material and acetaminophen and its use - Google Patents
Composition comprising a tramadol material and acetaminophen and its use Download PDF
USRE39221E1
USRE39221E1 US10/761,096 US76109604A USRE39221E US RE39221 E1 USRE39221 E1 US RE39221E1 US 76109604 A US76109604 A US 76109604A US RE39221 E USRE39221 E US RE39221E
US10/761,096
1991-09-06 Priority to US75592491A priority Critical
1992-11-10 Priority to US07/974,865 priority patent/US5336691A/en
2002-11-25 First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36710719&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE39221(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
2004-01-20 Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
2004-01-20 Priority to US10/761,096 priority patent/USRE39221E1/en
2006-04-21 Assigned to ORTHO-MCNEIL PHARAMACEUTICAL, INC. reassignment ORTHO-MCNEIL PHARAMACEUTICAL, INC. MERGER (SEE DOCUMENT FOR DETAILS). Assignors: MCNEILAB, INC., ORTHO PHARMACUETICAL CORPORATION
2006-04-24 Assigned to ORTHO-MCNEIL PHARMACEUTICAL, INC. reassignment ORTHO-MCNEIL PHARMACEUTICAL, INC. CORRECTIVE ASSIGNMENT TO CORRECT THE FIRST ASSIGNOR: "PHARMACUETICAL" SHOULD READ "PHARMACEUTICAL" AND ASSIGNEE: "PHARAMEUTICAL" SHOULD READ "PHARMACEUTICAL" PREVIOUSLY RECORDED ON REEL 017507 FRAME 0355. ASSIGNOR(S) HEREBY CONFIRMS THE CONVEYING AND RECEIVING PARTY DATA CONTAIN A TYPOGRAPHICAL ERROR. Assignors: MCNEILAB, INC., ORTHO PHARMACEUTICAL CORPORATION
2006-08-01 Publication of USRE39221E1 publication Critical patent/USRE39221E1/en
2008-09-04 Assigned to ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. reassignment ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. AGREEMENT FOR TRANSFER OF ASSETS AND BILL OF SALE Assignors: ORTHO-MCNEIL PHARMACEUTICAL, INC.
This case is related to application Ser. Nos. 7/759,259, filed Sep. 13, 1991, now U.S. Pat. No. 5,223,541 and 07/785,137, filed Oct. 30, 1991, now abandoned, and is a continuation-in-part of application serial No. 07/755,924, filed Sep. 6, 1991, now abandoned. Claims priority, application Germany, filed Apr. 2, 1963, C29547 IV b/12o and application Germany, filed Apr. 2, 1963, C29548 IVd/12p.
U.S. Pat. No. 3,652,589 discloses a class of analgesic cycloalkanol-substituted phenol esters having a basic amine group in the cycloalkyl ring. The compound (1RS, 2RS)-[(dimethylamino)-methyl]-1-(3-methoxy-phenyl)cyclohexanol, commonly known as tramadol, is specifically disclosed therein. A series of articles pertaining to the pharmacology, toxicology and clinical studies of tramadol are found in Arzneim. Forsch, (Drug Res.), 28(I), 114(1978). Driessen et al., Arch. Pharmacol., 341, R104 (1990) disclose that tramadol produces its analgesic effect through a mechanism that is neither fully opioid-like or non-opioid-like. The Abstracts of the VI th World Congress on Pain, Apr. 1-6 (1990), disclose that tramadol hydrochloride is an orally active pure agonist opioid analgesic. However, clinical experience indicates that tramadol lacks many of the typical side effects of opioid agonists, e.g., respiratory depression (W.-Vogel et al., Arzneim. Forsch. (Drug Res.), 28(I), 183 (1978)), constipation (I. Arend et al., Arzneim. Forsch, (Drug Res.), 28(I), 199 (1978)), tolerance (L. Flohe et, al., Arzeim. Forsch, (Drug Res.), 28(I), 213 (1978)), and abuse liability (T. Yanagita, Arzneim. Forsch, (Drug Res.), 28(I), 158 (1978)). When given at a dose of 50 mg by rapid i.v. injection, tramadol may produce certain side effects unique to tramadol including hot flushes and sweating. Despite these side effects, tramadol's combination of non-opioid and opioid activity makes tramadol a very unique drug. Tramadol is currently being marketed by Grunenthal GMBH as an analgesic.
Opioids have for many years been used as analgesics to treat severe pain. They, however, produce undesirable side effects and as a result cannot be given repeatedly or at high doses. The side effect problems are well documented in the literature. See, for example, J. Jaffe and W. Martin in chapter 15, “The Pharmacological Basis of Therapeutics”, editors L. Goodman and A. Gilman, 5th Edition, 245 (1975) wherein it is disclosed that morphine and its congeners, e.g., codeine, hydrocodone and oxycodone, are opioid agonist analgesics that exhibit side effects such as respiratory depression, constipation, tolerance and abuse liability.
As alternatives to using opioids, non-opioids such as acetaminophen (APAP) and aspirin are used as analgesics. APAP, like aspirin, is not subject to the tolerance, addiction and toxicity of the opioid analgesics. However, APAP and aspirin are only useful in relieving pain of moderate intensity, whereas the opioid analgesics are useful in relieving more intense pain; See Woodbury, D. and Fingl, E. in “The Pharmacological Basis of Therapeutics”, 5th Ed.; Goodman, L. and Gilman, A., Chapter 15, pages 325 (1975).
To reduce the side effect problems of opioids, opioids have been combined with other drugs including non-opioid analgesic agents, which lowers the amount of opioid needed to produce an equivalent degree of analgesic. It has been claimed that some of these combination products also have the advantage of producing a synergistic analgesic effect. For example, A. Takemori, Annals New York Acad. Sci., 281, 262 (1976) discloses that compositions including combinations of opioid analgesics with drugs other than analgesics exhibit a variety of effects, i.e., subadditive (inhibitory), additive or superadditive. R. Taber et al., J. Pharm. Expt. Thera., 169(1), 29 (1969) disclose that the combination of morphine and methadone, another opioid analgesic, exhibits an additive effect. U.S. Pat. No. 4,571,400 discloses that the combination of dihydrocodeine, an opioid analgesic, and ibuprofen, a non-opioid analgesic, provides super-additive effects when the components are within certain ratios. A. Pircio et al., Arch. Int. Pharmacodyn., 235, 116 (1978) report superadditive analgesia with a 1:125 mixture of butorphanol, another opioid analgesic, and acetaminophen (APAP), a non-opioid analgesic, whereas a 1:10 mixture did not show any statistically significant superadditive analgesia.
Combinations of non-opioid analgesics have also been prepared to avoid the side effects associated with opioids, and the combinations are noted to have the benefit of requiring less of each ingredient and in producing superadditive effects. G. Stacher et. al., Int. J. Clin. Pharmacol. Biopharmacy, 17, 250 (1979) report that the combination of non-opioid analgesics, i.e., tolmetin and APAP, allows for a marked reduction in the amount of tolmetin required to produce analgesia. In addition, U.S. Pat. No. 4,260,629 discloses that an orally administered composition of APAP and zomepirac, a non-opioid analgesic, in a particular weight ratio range produces a superadditive relief of pain in mammals. Furthermore, U.S. Pat. No. 4,132,788 discloses that 5-aroyl-1-(lower)alkylpyrrole-2-acetic acid derivatives, non-opioid analgesics, when combined with APAP or aspirin exhibit superadditive antiarthritic activity. However, there have been warnings against the daily consumption of non-opioid analgesic mixtures and of the consumption of a single non-opioid analgesic in large amounts or over long periods (see, D. Woodbury and E. Fingl at page 349).
The prior art, however, does not disclose that tramadol an ‘atypical’ opioid analgesic, can or should be combined with another analgesic to lessen the side effects of each or to yield a composition comprising a tramadol material and another analgesic that exhibits superadditive analgesia.
FIG. 1 is an isobologram showing the analgesic effect of tramadol hydrochloride and acetaminophen composition on the acetylcholine-induced abdominal constriction in mice.
The present invention is directed to compositions comprising a tramadol material and acetaminophen. The tramadol material is any one of (1R, 2R or 1S, 2S)-(dimethylaminomethyl)-1-(3-methoxyphenyl)-cyclohexanol (tramadol), its N-oxide derivative (“tramadol N-oxide”), and its O-desmethyl derivative (“O-desmethyl tramadol”) or mixtures thereof. It also includes the individual stereoisomers, mixtures of stereoisomers, including the racemates, pharmaceutically acceptable salts of the amines, such as the hydrochloride salts, solvates and polymorphs of the tramadol material. Tramadol is commercially available from Grunenthal or may be made by the process described in U.S. Pat. No. 3,652,589, which is herein incorporated by reference.
Tramadol N-oxide is prepared by treating tramadol as a free base with an oxidizing agent, e.g., hydrogen peroxide (30%), in an organic solvent, e.g., methanol or isopropanol, with, bit preferably without heating. See, “Reagents For Organic Synthesis”, 1, 471, Fieser & Fieser eds. Wiley N.Y.; (1987), B. Kelentey et al., Arzneim, Forsch., 7, 594 (1957). With heating, the reaction takes about 1 hour, whereas without heating the reaction takes about 3 days. Following the oxidation, the mixture is treated with an agent, e.g. PtO2 or preferably Pt/C, for about a day, to destroy the excess hydrogen peroxide. The mixture is filtered, followed by the evaporation of the filtrate and then the residue is recrystallized from an organic solvent mixture, e.g., methylene chloride/ethyl acetate.
O-Desmethyl tramadol is prepared by treating tramadol as a free base under O-desmethylating reaction conditions, e.g., reacting it with a strong base such as NaH or KH, thiophenol and diethylene glycol (DEG) with heating to reflux. See, Wildes et al., J. Org. Chem., 36, 721 (1971). The reaction takes about an hour, followed by the cooling and then quenching in water of the reaction mixture. The quenched mixture if acidified, extracted with an organic solvent such as ethyl ether, basified and then extracted with a halogenated organic solvent such as methylene chloride. The extract is then dried and the solvent evaporated to yield the O-desmethyl product, which may then be short-path distilled, converted to its corresponding salt, e.g., treated with an acidified (HCl/ethanol) solution, and recrystallized from an organic solvent mixture, e.g., ethanol/ethyl ether.
The pharmacology of acetaminophen is reviewed by B. Ameer et al., Ann. Int. Med., 87, 202 (1977), and the preparation of acetaminophen is disclosed in U.S. Pat. No. 2,998,450, which is incorporated herein by reference.
The tramadol/APAP formulations according to the present invention may also contain therapeutically effective amounts of one or more other pharmaceutical actives including but not limited to decongestants or bronchodilators (such as pseudoephedrine, phenylpropanolamine, phenylephrine and pharmaceutically acceptable salts thereof), antitussives (such as caraminophen, dextromethorphan and pharmaceutically acceptable salts thereof) antihistamines (such as chlorpheniramine, brompheniramine, dexchlorpheniramine, dexbromphreniramine, triprolidine, doxylamine, tripelennamine, cyproheptadine, hydroxyzine, pyrilamine, azatadine, promethazine and pharmaceutically acceptable salts thereof), non-sedating antihistamines (such as acrivastine, astemizole, cetirizine, ketotifen, loratidine, temelastine, terfenadine (including the metabolites disclosed in U.S. Pat. No. 4,254,129 and 4,284,957 hereby incorporated by reference) and pharmaceutically acceptable salts thereof), muscle relaxants (such as glycerylmonether SMRS, methocarbamol, mephenesin, mephenesin carbamate, mephenesin acid succinate, cyclobenzaprine, chlorphenesin carbamate, chlorzoxazone or pharmceutically acceptable salts thereof) and suspected adjuvants (such as diphenhyhdramine, caffeine, xanthine derivatives (including those disclosed in U.S. Pat. No. 4,558,051, hereby incorporated by reference) and pharmaceutically acceptable salts thereof) and combinations of any of the aforesaid pharmaceuticals. The aforesaid pharmaceuticals may be combined with a tramadol/acetaminophen formulation for the treatment of such ailments as allergies, sleep disorders, cough, colds, cold-like and/or flu symptoms in mammals including humans.
Pharmaceutical compositions comprising the tramadol material and acetaminophen and when desired other pharmaceutical actives in an intimate admixture with a pharmaceutical carrier can be prepared according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous, oral or parenteral. The composition may also be administered by means of an aerosol. In preparing the compositions in an oral dosage form, any of the usual pharmaceutical media may be employed. For example, in the case of oral liquid preparations (such as suspensions, elixirs and solution), water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used. In the case of oral solid preparations (such as, for example, powders, capsules an tablets), carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like, may be used. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar-coated or enteric-coated by standard techniques. For parenterals, the carrier will usually comprise sterile water, though other ingredients, for example, to aid solubility or for preservative purposes, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions will generally be in the form of a dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, containing from 0.1 to about 800 mg/kg, and preferably from about 0.3 to 200 mg/kg of the active ingredients. The dosage unit is calculated based on the amount of active which may be given to a 70 kg human subject in a single dose. The pharmaceutical compositions may be given at a daily dosage of from about 10 to 6000 mg/kg/day. However, it will be appreciated that the precise dose of the active ingredients will vary depending upon the relative amounts of active components being used. In the case wherein one or more other pharmaceutical components are added to the tramadol/APAP composition those components may be added in amounts known in the art and may be given at dosages conventional for such components. For example, decongestants and bronchodilators may be given in a single dosage of from about 12.5 to 75 mg/kg and at a daily dosage of from about 60 to 150 mg/kg/day. Antitussives may be given in a single dosage of from about 2.5 to 30 mg/kg and at a daily dosage of from about 20 to 120 mg/kg/day. Antihistamines may be given in a single dosage of from about 1 to 50 mg/kg and at a daily dosage of from about 4 to 600 mg/kg/day. Non-sedating antihistamines may be given in a single 1 dosage of from about 8 to 30 mg/kg and at a daily dosage of from about 30 to 120 mg/kg/day. Muscle relaxants may be given at a single dosage of from about 10 to 1500 mg/kg and at a daily dosage of from about 60 to 8000 mg/kg/day. Adjuvants may be given in a single dosage of from about 1 to 25 mg/kg and at a daily dosage of from about 1 to 100 mg/kg/day.
The following experimental examples describe the invention in greater particularly and are intended to be a way of illustrating but not limiting the invention.
EXAMPLE 1 Preparation of the Combined Doses of Tramadol and APAP
The preparation of different ratios of a tramadol/APAP combination is effected by first preparing a stock solution of tramadol having a concentration expressed in mgdrugs per 10 mL of distilled water. For example, 8 mg of tramadol as the free base is dissolved per 10 mL of water to yield the highest dose of tramadol stock solution. The stock solution of the tramadol is then diluted with a sufficient amount of distilled water to prepare the lower doses of the tramadol per 10 mL of distilled water. The combinations are then made by adding 10 mL of each dilution to the appropriate mg of APAP to achieve the desired ratio of tramadol to APAP. For the 1:50 example: 400 mg of APAP as the free base is suspended with 10 mL of the 8 mg tramadol solution and 2 drops of TWEEN 80, a pharmacological dispersant, manufactured by Fisher Scientific Company, to yield the 1:50 ratio, i.e. (8 mg:400 mg) combination per 10 mL of water. Each ratio was prepared separately in a similar manner and injected in a volume of 10 mL/kg per mouse.
EXAMPLE 2 Preparation of the Combined Doses of Tramadol N-oxide and APAP
First, tramadol N-oxide was prepared as set forth hereinafter. Tramadol hydrochloride (0.5 mol) was converted to its free base in basified water (pH>9) and then extracted with ether. The ether was evaporated to yield the crystalline hydrate of tramadol. The solid was then heated with steam under a high vacuum to remove as much water as possible to yield 131.5 g of material. The material was dissolved in methanol (500 mL) and 65 g of 30% H2O2 was added. The solution was stirred for 3 hours and then an additional 65 g of the 30% H2O2 was added. The reaction was stirred for 2.5 days at room temperature. Approximately 10 mg of PtO2 on carbon (use of Pt/C is suggested for its ease of removal) was added to the reaction mixture, and very gentle foaming took place. An additional 10 mg of PtO2 was added and the reaction mixture was stirred overnight and then filtered thru a filter aid. The filtrate was concentrated under vacuum while being heated to a temperature of <40° C. The residue was taken up in methylene chloride. Since the methylene chloride solution contained some colloidial platinum, the solution was diluted with ethyl acetate to 1 L and filtered through a nylon filter membrane (0.45μ pore size) to yield a clear colorless filtrate. The filtrate was concentrated to 600 mL, and then ethyl acetate was added continuously to maintain a volume of 800 mL while the solution was heated until a vapor temperature of 74° C. was reached. The solution was then cooled to room temperature. The solid was collected by filtration, washed with ethyl acetate and dried in vacuo to yield 126.6 g of the tramadol N-oxide (mp. 159.5°-160° C.).
C16H25NO3 Theor.: C, 68.78; H, 9.27; N, 5.01 Found: C, 68.65; H, 9.22; N, 4.99
The preparation of different ratios of a tramadol N-oxide/APAP combination is effected by first preparing a stock solution of tramadol-N-oxide having a concentration expressed in mgdrugs per 10 mL of distilled water. For example, 8 mg of tramadol N-oxide as the free base is dissolved per 10 mL of water to yield the highest dose of tramadol stock solution. The stock solution of the tramadol-N-oxide is then diluted with a sufficient amount of distilled water to prepare the lower doses of the tramadol N-oxide per 10 mL of distilled water. The combinations are then made by adding 10 mL of each dilution to the appropriate mg of APAP to achieve the desired ratio of tramadol N-oxide to APAP. For the 1:50 example: 400 mg of APAP as the free base is suspended with 10 mL of the 8 mg tramadol N-oxide solution and 2 drops of TWEEN 80, a pharmacological dispersant, manufactured by Fisher Scientific Company, to yield the 1:50 ratio, i.e., (8 mg:400 mg) combination per 10 mL of water. Each ratio was prepared separately in a similar manner and injected in a volume of 10 mL/kg per mouse.
Example 3 (−) and (+) Enantiomers of O-Desmethyl Tramadol: Their Syntheses and the Preparation of Doses of O-Desmethyl Tramadol-with APAP
First, O-desmethyl tramadol was prepared as set forth hereinafter. Diethylene glycol (125 mL) was added with cooling to potassium hydride (9.5 g) with the temperature being maintained at <50° C. To the solution was added thiophenol (10 mL) dissolved in diethylene glycol (25 mL), and then (−)-tramadol as the free base (9.3 g) in diethylene glycol (50 mL) was added. The final reaction mixture was heated slowly to reflux for 45 minutes. The mixture was cooled and then quenched into water. The pH was adjusted to about 3, and the mixture was extracted with ethyl ether. The pH was readjusted to about 8 and the resulting mixture was extracted 5 more times with methylene chloride. The extract was dried and the methylene chloride was evaporated to yield 4.6 g of the title compound as an oil. The oil was distilled (Kugelrohr), dissolved in tetrahydrofuran, treated with an ethanol/HCl solution to give 2.3 g of the salt. The salt was recrystallized from ethanol/ethyl ether and dried to yield 1.80 g of the salt of the (−) enantiomer of O-desmethyl tramadol (mp. 242°-3° C.), [α]D 25=−32.9 (C=1, EtOH).
C15H23NO2.HCl Theor.: C, 63.04; H, 8.46; N, 4.90 Found: C, 63.00; H, 8.51; N, 4.94
To prepare the (+) enantiomer of the title compound, the reaction was run under the same conditions except that (+)-tramadol as the free base was used instead of the (−)-tramadol to yield 2.8 g of the (+) enantiomer of O-desmethyl tramadol (mp. 242°-3° C.) [α]D 25=+32.2 (C=1, EtOH).
C15H23NO2.HCl Theor.: C, 63.04; H, 8.46; N, 4.90 Found: C, 63.14; H, 8.49; N, 4.86
The preparation of different ratios of a O-desmethyl/APAP combination is effected by first preparing a stock solution of O-desmethyl tramadol having a concentration expressed in mgdrugs per 10 mL of distilled water. For example, 8 mg of O-desmethyl tramadol as the free base is dissolved per 10 mL of water to yield the highest dose of O-desmethyl tramadol stock solution. The stock solution of the O-desmethyl tramadol is then diluted with a sufficient amount of distilled water to prepare the lower doses of the O-desmethyl tramadol per 10 mL of distilled water. The combinations are then made by adding 10 mL of each dilution to the appropriate mg of APAP to achieve the desired ratio of O-desmethyl tramadol to APAP. For the 1:50 example: 400 mg of APAP as the free base is suspended with 10 mL of the 8 mg O-desmethyl tramadol solution and 2 drops of TWEEN 80, a pharmacological dispersant, manufactured by Fisher Scientific Company, to yield the 1:50 ratio, i.e., (8 mg: 400 mg) combination per 10 mL of water. Each ratio was prepared separately in a similar manner and injected in a volume of 10 ml/kg per mouse.
EXAMPLE 4 Analgesic Activity
Mice, intubated with various doses of tramadol hydrochloride alone, acetaminophen alone, combined doses of tramadol hydrochloride and acetaminophen, or vehicle such as distilled water, or distilled water containing 2% by volume of Tween 80, were injected intraperitoneally with a challenge dose of acetylcholine bromide. The acetylcholine was completely dissolved in distilled water at a concentration of 5.5 mg/kg and injected at the rate of 0.20 mL/20 g. For scoring purposes an “abdominal constriction” was defined as a contraction of the abdominal musculature accompanied by arching of the back and extension of the limbs. The mice were observed 10 minutes for the presence or absence of the abdominal constriction response beginning immediately after receiving the acetylcholine dose, which was 30 minutes after receiving the oral administration of tramadol hydrochloride, acetaminophen, combined doses of tramadol hydrochloride and acetaminophen, or vehicle. Each mouse was used only once.
The analysis of possible superadditivity for the compositions at each fixed ratio was determined as disclosed by R. J. Tallarida et al., Life Sci., 45, 947 (1989). This procedure involved the determination of the total amount in the mixture that is required to produce a specified level of effect, such as 50% (ED50mix), and the corresponding total amount that would be expected under simple additivity (ED50add). Where it was established that ED50mix<ED50add for a specific fixed-ratio, then that composition ratio was superadditive. Both the quantities ED50mix and ED50add were random variables; ED50mix was estimated from the dose-response curve for a specific fixed-ratio; ED50add was obtained by combining the ED50 estimates for the two drugs under additivity. ED50mix was then compared to ED50add via a Student's t-test. The ED50 value for tramadol hydrochloride alone was 5.5(4.8-6.4) mg/kg. The ED50 value for acetaminophen alone was 164.3 (122.7-219.9) mg/kg.
The interaction of tramadol hydrochloride and acetaminophen on the acetylcholine-induced abdominal constriction in mice was demonstrated by the data in Table I and is shown in the Loewe isobologram, FIG. I, (see, S. Loewe, Pharm. Rev., 9; 237 (1957) regarding the preparation and basis of an isobologram). In FIG. 1, the diagonal line joining the ED50 values of the two drugs given separately represents the simple additivity of effects at different component ratios. The dotted lines adjacent to the diagonal line define the 95% confidence interval. ED50 values falling under the curve (between the line and the origin) indicate superadditivity, i.e., unexpected enhancement of effects. The diagonal dashed lines radiating from the origin represent the dose ratios of APAP to tramadol hydrochloride used in mice receiving the combined drug dosages. The bars through the ED50 points for the tramadol and APAP composition represent the 95% confidence intervals of the ED50 value. The experimental data as represented in FIG. I establishes that composition having a ratio of tramadol to APAP from 1:1 to 1:1600 (represented by the curved line) give unexpectedly enhanced activity since ED50mix is less than ED50add.
DRUG COMBINATIONS DOSE (mg/kg, p.o.) ED50 30 min (95% CI's)
6 0 20/45 5.5
1000:1  3.75 0.00375 1/13
100:1  1.875 0.01875 0/15
15 0/15 15/15
20:1  1.875 0.09375 0.15
15 15 15/15
APAP only 0 30 2/15
0 100 13/30 — 164.3
1. A pharmaceutical composition comprising a tramadol material and acetaminophen, wherein the ratio of the tramadol material to acetaminophen is a weight ratio from about 1:1 to about 1:1600.
2. The pharmaceutical composition of claim 1 wherein the tramadol material is tramadol hydrochloride.
3. The pharmaceutical composition of claim 2 wherein the tramadol hydrochloride is racemic.
4. The pharmaceutical composition of claim 1 wherein the weight ratio is about 1:1.
5. The pharmaceutical composition of claim 1 wherein the weight ratio is from about 1:5 to about 1:1600.
6. The pharmaceutical composition of claim 5 wherein the A pharmaceutical composition comprising a tramadol material and acetaminophen, wherein the ratio of the tramadol material to acetaminophen is a weight ratio is of about 1:5.
7. The pharmaceutical composition of claim 5 wherein the weight ratio is from about 1:19 to about 1:800.
8. The pharmaceutical composition of claim 7 wherein the weight ratio is from about 1:19 to about 1:50.
9. The pharmaceutical composition of claim 1 further comprising a pharmaceutically acceptable carrier.
10. The pharmaceutical composition of claim 1 further comprising a decongestant or bronchodilator.
11. The pharmaceutical composition of claim 1 further comprising an antitussive.
12. The pharmaceutical composition of claim 1 further comprising an antihistamine or a non-sedating antihistamine.
13. The pharmaceutical composition of claim 1 further comprising a muscle relaxant.
14. The pharmaceutical composition of claim 1 further comprising a sleep aid.
15. A method for treating a pain in a mammal comprising an administration administering to the mammal an effective amount of the pharmaceutical composition of claim 1 claim 6.
16. A pharmaceutical composition comprising an active ingredient that consists essentially of tramadol and acetaminophen, wherein the ratio of tramadol to acetaminophen is a weight ratio from about 1:1 to about 1:1600.
17. The pharmaceutical composition of claim 16 wherein the tramadol is racemic.
18. The pharmaceutical composition of claim 16 wherein the tramadol is present as its hydrochloride salt.
19. The pharmaceutical composition of claim 18 wherein the tramadol hydrochloride is racemic.
20. The pharmaceutical composition of claim 16 wherein said active ingredient consists essentially of an admixture of said tramadol and said acetaminophen.
21. The pharmaceutical composition of claim 16 wherein the weight ratio is about 1:1.
22. The pharmaceutical composition of claim 16 wherein the weight ratio is from about 1:5 to about 1:1600.
23. The pharmaceutical composition of claim 16 wherein the weight ratio is about 1:5.
24. The pharmaceutical composition of claim 16 comprising a pharmaceutically acceptable carrier.
25. The pharmaceutical composition of claim 16 that is in the form of a powder.
26. The pharmaceutical composition of claim 16 that is in the form of a capsule.
27. The pharmaceutical composition of claim 16 that is in the form of a tablet.
28. The pharmaceutical composition of claim 16 that is in the form of a suspension.
29. The pharmaceutical composition of claim 16 that is in the form of a solution.
30. A method for treating pain in a mammal comprising administering to the mammal an effective amount of the pharmaceutical composition of claim 16.
31. A pharmaceutical composition comprising an active ingredient that consists essentially of tramadol and acetaminophen, wherein the ratio of tramadol to acetaminophen is a weight ratio from about 1:5 to about 1:50.
32. The pharmaceutical composition of claim 31 wherein the tramadol is racemic.
33. The pharmaceutical composition of claim 31 wherein the tramadol is present as its hydrochloride salt.
34. The pharmaceutical composition of claim 33 wherein the tramadol hydrochloride is racemic.
35. The pharmaceutical composition of claim 31 wherein said active ingredient consists essentially of an admixture of said tramadol and said acetaminophen.
36. The pharmaceutical composition of claim 31 comprising a pharmaceutically acceptable carrier.
37. The pharmaceutical composition of claim 31 that is in the form of a powder.
38. The pharmaceutical composition of claim 31 that is in the form of a capsule.
39. The pharmaceutical composition of claim 31 that is in the form of a tablet.
40. The pharmaceutical composition of claim 31 that is in the form of a suspension.
41. The pharmaceutical composition of claim 31 that is in the form of a solution.
42. A method for treating pain in a mammal comprising administering to the mammal an effective amount of the pharmaceutical composition of claim 31.
43. A pharmaceutical composition comprising an active ingredient that consists essentially of tramadol and acetaminophen, wherein the ratio of tramadol to acetaminophen is a weight ratio from about 1:5 to about 1:19.
44. The pharmaceutical composition of claim 43 wherein the tramadol is racemic.
45. The pharmaceutical composition of claim 43 wherein the tramadol is present as its hydrochloride salt.
46. The pharmaceutical composition of claim 45 wherein the tramadol hydrochloride is racemic.
47. The pharmaceutical composition of claim 43 wherein said active ingredient consists essentially of an admixture of said tramadol and said acetaminophen.
48. The pharmaceutical composition of claim 43 comprising a pharmaceutically acceptable carrier.
49. The pharmaceutical composition of claim 43 that is in the form of a powder.
50. The pharmaceutical composition of claim 43 that is in the form of a capsule.
51. The pharmaceutical composition of claim 43 that is in the form of a tablet.
52. The pharmaceutical composition of claim 43 that is in the form of a suspension.
53. The pharmaceutical composition of claim 43 that is in the form of a solution.
54. A method for treating pain in a mammal comprising administering to the mammal an effective amount of the pharmaceutical composition of claim 43.
55. A pharmaceutical composition comprising an active ingredient that consists essentially of tramadol and acetaminophen, wherein the ratio of tramadol to acetaminophen is a weight ratio from about 1:19 to about 1:50.
56. The pharmaceutical composition of claim 55 wherein the tramadol is racemic.
57. The pharmaceutical composition of claim 55 wherein the tramadol is present as its hydrochloride salt.
58. The pharmaceutical composition of claim 57 wherein the tramadol hydrochloride is racemic.
59. The pharmaceutical composition of claim 55 wherein said active ingredient consists essentially of an admixture of said tramadol and said acetaminophen.
60. The pharmaceutical composition of claim 55 comprising a pharmaceutically acceptable carrier.
61. The pharmaceutical composition of claim 55 that is in the form of a powder.
62. The pharmaceutical composition of claim 55 that is in the form of a capsule.
63. The pharmaceutical composition of claim 55 that is in the form of a tablet.
64. The pharmaceutical composition of claim 55 that is in the form of a suspension.
65. The pharmaceutical composition of claim 55 that is in the form of a solution.
66. A method for treating pain in a mammal comprising administering to the mammal an effective amount of the pharmaceutical composition of claim 55.
67. A pharmaceutical composition consisting essentially of:
an active ingredient that consists of racemic tramadol hydrochloride and acetaminophen, wherein the ratio of racemic tramadol hydrochloride to acetaminophen is from about 1:5 to about 1:19; and
68. The pharmaceutical composition of claim 67 that is in the form of a capsule.
69. The pharmaceutical composition of claim 67 that is in the form of a tablet.
70. The pharmaceutical composition of claim 67 that is in the form of a suspension.
71. The pharmaceutical composition of claim 67 that is in the form of a solution.
72. A method for treating pain in a mammal comprising orally administering to the mammal an effective amount of the pharmaceutical composition of claim 67.
73. A method for treating pain in a mammal comprising orally administering to the mammal an effective amount of the pharmaceutical composition of claim 68.
74. A method for treating pain in a mammal comprising orally administering to the mammal an effective amount of the pharmaceutical composition of claim 69.
75. A method for treating pain in a mammal comprising orally administering to the mammal an effective amount of the pharmaceutical composition of claim 70.
76. A method for treating pain in a mammal comprising orally administering to the mammal an effective amount of the pharmaceutical composition of claim 71.
US10/761,096 1991-09-06 2004-01-20 Composition comprising a tramadol material and acetaminophen and its use Expired - Lifetime USRE39221E1 (en)
US75592491A true 1991-09-06 1991-09-06
US07/974,865 US5336691A (en) 1991-09-06 1992-11-10 Composition comprising a tramadol material and acetaminophen and its use
US10/761,096 USRE39221E1 (en) 1991-09-06 2004-01-20 Composition comprising a tramadol material and acetaminophen and its use
US07/974,865 Reissue US5336691A (en) 1991-09-06 1992-11-10 Composition comprising a tramadol material and acetaminophen and its use
USRE39221E1 true USRE39221E1 (en) 2006-08-01
ID=36710719
US10/761,096 Expired - Lifetime USRE39221E1 (en) 1991-09-06 2004-01-20 Composition comprising a tramadol material and acetaminophen and its use
US (1) USRE39221E1 (en)
USRE40602E1 (en) * 1997-12-24 2008-12-09 Panasonic Corporation Semiconductor device having a ferroelectric TFT and a dummy element
US20090028873A1 (en) * 2007-07-27 2009-01-29 Auspex Pharmaceuticals, Inc. Substituted cyclohexanols
EP2377514A2 (en) 2010-04-19 2011-10-19 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Liquid parenteral formulation comprising a tramadol material and paracetamol
KR20130137720A (en) 2008-10-27 2013-12-17 알자 코퍼레이션 Extended release oral acetaminophen/tramadol dosage form
TWI620577B (en) * 2016-11-23 2018-04-11
JPS5492631A (en) 1977-12-27 1979-07-23 Kowa Co Analgestic
JPS55129225A (en) 1979-03-22 1980-10-06 Merck & Co Inc Combination of phenylbenzoic acid compound and acetaminophene for analgesic and antiinflammatory treatment
US4260629A (en) 1979-10-25 1981-04-07 E. I. Du Pont De Nemours And Company Treating pain with acetaminophen and 1,4-dimethyl-5-p-chlorobenzoyl-pyrrole-2-acetic acid
JPS57128626A (en) 1981-01-30 1982-08-10 Morishita Seiyaku Kk Analgesic composition
US4631284A (en) 1984-11-19 1986-12-23 Mallinckrodt, Inc. Acetaminophen compositions containing low doses of chlorpheniramine maleate, method for preparing same and tablets formed therefrom
US4730007A (en) 1985-09-04 1988-03-08 Seymour Ehrenpreis Novel analgesic compositions
EP0358107A2 (en) 1988-09-07 1990-03-14 BASF Aktiengesellschaft Process for the preparation of pharmaceutical tablets
US4943565A (en) 1986-09-15 1990-07-24 Bristol-Myers Squibb Company Analgesic tablet of aspirin and caffeine containing low-substituted hydroxypropyl cellulose
EP0227836B1 (en) 1985-06-24 1991-12-27 Teijin Limited Sustained releasing patch
US5468744A (en) 1991-09-06 1995-11-21 Mcneil Lab, Inc. Composition comprising a tramadol material and any of codeine, oxycodone or hydrocodone and their use
US6562865B1 (en) 1999-08-20 2003-05-13 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
2004-01-20 US US10/761,096 patent/USRE39221E1/en not_active Expired - Lifetime
EP0017102A1 (en) 1979-03-22 1980-10-15 Merck &amp; Co., Inc. Composition containing a phenyl benzoic acid compound and acetaminophen combination for the treatment of pain and inflammation and process for preparing the same
JPS55154917A (en) 1979-05-18 1980-12-02 Du Pont Analgesic mixture
Budavari, Susan, editor, The Merck Index, 11th Edition, Merck & Co., Inc., Rahway, N.J., 1989, pp. 8 and 1506.
In the United States District Court For The District of New Jersey, -, Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Cynthia G. McCormick (Jan. 13, 2005).
In the United States District Court for the District of New Jersey, Civil Action No. 02-2707(JCL), Ortho-McNeil Pharmaceutical, Inc., v. Kali Laboratories, Inc:. Defendant Kali Laboratories, Inc.'s Second Amended Answer, Counterclaim, and Jury Demand and Defendants Par Pharmaceutical Companies, Inc.'s and Par Pharmaceutical, Inc.'s Answer, Counterclaim, and Jury Demand, Aug. 25, 2005.
In the United States District Court for the District of New Jersey, Civil Action No. 02-2707(JCL), Ortho-McNeil Pharmaceutical, Inc., v. Kali Laboratories, Inc:. First Amended Complaint for Patent Infringement, Jul. 27, 2005.
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Abraham Sunshine (Mar. 12, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Charles E. Inturrisi (Feb. 25, 2005).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Clark D. McKeever (Nov. 11, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of DOnald R. Stanski, M.D. (Jan. 5, 2005) [Redacted].
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Dr. Eric Peter Smith (Dec. 10, 2004) [Redacted].
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Ellen Codd (Mar. 31, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Fredrick Minn (Mar. 26, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Gary P. Thomas (Dec. 3, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Gordon Rausser, Ph.D. (Jan. 14, 2005).
In the United States District Court for the District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Harry F. Manbeck, Jr. (Feb. 2, 2005).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Howard T. Thaler (Jan. 25, 2005) [Redacted].
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of James C. Morrison (Jan. 10, 2005).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Jeffrey A. Gudin, M.D. (Jan. 7, 2005).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Laura Glauda (Mar. 5, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Lee S. Simon (Dec. 8, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Leslie S. Zun (Nov. 9, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Marc Kamin (Dec. 4, 2003).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Marvin Ladov (Feb. 11, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Michael Sofocleous (Dec. 16, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Natasha Rogozenski (Mar. 30, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Nicholas Landekic (Apr. 5, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Ralph Palo (Mar. 18, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Ramin Valian (Mar. 30, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Ravi Desiraju (Jan. 21, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Rebecca Martinez (Mar. 23, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Richard P. Rozek, Ph.D. (Dec. 14, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Robert B. Raffa (2nd Day) (Apr. 21, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Robert M. Bennett, M.D. (Jan. 12, 2005).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Robert Medve, M.D. (Dec. 2, 2003).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Ronald Tallarida, Ph.D, (Mar. 24, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Stephen Cooper, Ph.D. (Mar. 26, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Deposition of Stephen Grond (Dec. 21, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Expert Report of Clark D. McKeever (Jul. 15, 2004), with attached exhibits 1 thru 17.
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Expert Report of Cynthia G. McCormick (Nov. 18, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Expert Report of Donald R. Stanski (Jun. 15, 2004), with attached exhibits 1 thru 39 [Redacted].
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Expert Report of Dr. Lee S. Simon (Oct. 6, 2004), with attached exhibits 1, 2.
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Expert Report of Dr. Robert M. Bennett to address new issues raised by Drs. Thomas and Simon (Nov. 18, 2004), with attached exhibits 1 thru 6.
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Expert Report of Eric Smith (Jun. 14, 2004), with attached exhibits 1 thru 39.
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Expert Report of Gary P. Thomas, M.D. on Behalf of Defendant Kali Laboratories, (Oct. 11, 2004), with attached exhibits 1 thru 3.
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Expert Report of Gordon Rausser, Ph.D. (Oct. 8, 2004), with attached exhibits 1 thru 10.
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Expert Report of James Morrison on Behalf of Defendant Kali Laboratories, Part 1 of 2, and Part 2 of 2 (Sep. 22, 2004), with attached exhibits 1 thru 25.
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Expert Report of Jeffrey A. Gudin, MD (Jul. 15, 2004), with attached exhibits 1 thru 33.
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Expert Report of Leslie S. Zun (Jul. 15, 2004), with attached exhibits 1 thru 24, 25 thru 46.
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Expert Report of Richard P. Rozek, Ph.D. (Jul. 19, 2004), with attached exhibits A thru Q [Redacted].
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Expert Report of Robert M. Bennett (Jul. 13, 2004), with attached exhibits 1 thru 46.
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Fourth Expert Report of Donald R. Stanski, M.D. (Nov. 18, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Fourth Expert Report of Eric Smith, Ph.D. (Nov. 17, 2004), with attached exhibits Bates Numbers ES-RR3-0001-ES-RR3-0002.
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Ortho-McNeil's Brief in Opposition to Kali's Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Pat. No. 5,336,691: Claim 6 (Jul. 21, 2004) [Redacted].
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Ortho-McNeil's Brief in Opposition to Kali's Motion for Summary Judgment of Invalidity Under the 35 U.S.C. § 102(b) Public Use Bar (Jul. 21, 2004) [Redacted].
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Ortho-McNeil's Rule 56.1 Statement of Disputed Material Facts in Opposition to Defendant Kali's Laboratories' Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Pat. No. 5,336,691: Claim 6 (Jul. 21, 2004) [Redacted].
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Ortho-McNeil's Statement of Material Facts in Dispute With Respect to Kali's Motion for Summary Judgment of Invalidity Under the 35 U.S.C. § 102(b) Public Use Bar (Jul. 21, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Ortho-McNeil's Surreply in Opposition to Kali's Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Pat. No. 5,336,691: Claim 6 (Sep. 21, 2004) [Redacted].
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Rebuttal Expert Report of Donald R. Stanski (Jul. 19, 2004), with attached exhibits 1 thru 34.
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Rebuttal Expert Report of Eric Smith, Ph.D. (Jul. 14, 2004), with attached exhibits 1 thru 12.
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Rebuttal Expert Report of Richard P. Rozek, Ph.D. (Nov. 19, 2004), with attached exhibits Bates Nos. OMP RR RR 0001 thru, OMP RR RR 0285.
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Rebuttal Report of Michael Sofocleous (Jul. 19, 2004), with attached exhibits A thru L.
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Reply Brief in Support of Defendant Kali Laboratories' Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Pat. No. 5,336,691: Claim 6 (Aug. 23, 2004) [Redacted].
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Reply Brief in Support of Defendant Kali Laboratories' Motion for Summary Judgment of Invalidity Under the 35 U.S.C. § 102(b) Public Use Bar (Aug. 23, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Rule 56.1 Statement of Undisputed Facts for Defendant Kali Laboratories' Motion for Summary Judgment of Invalidity Under the 35 U.S.C. § 102(b) Public Use Bar (May 28, 2004) [Redacted].
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Second Expert Report of Dr. Charles E. Inturrisi (Jul. 15, 2004), 3 pages.
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Second Expert Report of Howard T. Thaler, Ph.D. (Jul. 19, 2004),[Redacted].
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Second Rebuttal Report of Eric Smith, Ph.D. (Oct. 8, 2004), with attached exhibits Bates Nos. ES-RR2-0001 thru ES-RR2-0011 [Redacted].
In the United States District Court for the District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Supplemental Expert Report of Harry F. Manbeck, Jr. Oct. 11, 2004, 2 pages.
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Third Expert Report of Donald R. Stanski, M.D. (Oct. 11, 2004), with attached exhibits Bates No. DS-RR2-0001.
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Third Expert Report of Dr. Charles E. Inturrisi (Sep. 15, 2004), with attached exhibits 16 thru 19.
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: Third Expert Report of Howard T. Thaler, Ph.D. (Sep. 27, 2004).
In the United States District Court For The District of New Jersey, Civil Action No. 02-5707 (JCL), Ortho-McNeil Pharmaceutical, Inc. v. Kali Laboratories, Inc.: vol. 1A of Materials Supporting Ortho-McNeil's Oppositions to Kali's Motions for Summary Judgment: Declaration of Jeffrey P. Kushan (Part 1 of 2),with attachments 1 thru 9, Jul. 21, 2004, vol. 1B of Materials Supporting Ortho-McNeil's Oppositions to Kali's Motions for Summary Judgment: Declaration of Jeffrey P. Kushan (Part 2 of 2) with attachments 10 thru 30, vol. 1C pf Materials Supporting Ortho-McNeil's Oppositions to Kali's Motion for Summary Judgment-with attachments Tabs 1 thru 4 (all dated on or about Jul. 21, 2004) [Redacted].
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Ortho-McNeil Pharmaceutical, Inc., v. Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA, Inc. Rule 56.1 Statement of Undisputed Material Facts in for Defendants Teva Pharmaceutical Industries Ltd. And Teva Pharmaceutical USA, Inc.'s Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Pat. No. 5,336,691: Claim 6 (Jan. 18, 2005) [Redacted].
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Ortho-McNeil Pharmaceutical, Inc., v. Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA, Inc., Brief in Support of Teva Pharmaceutical Industries Ltd. And Teva Pharmaceutical USA, Inc.'s Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Patent No. 5,336,691: Claim 6 (Jan. 18, 2005) [Redacted].
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Ortho-McNeil Pharmaceutical, Inc., v. Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA, Inc., Declaration of William L. Warren in Support of Defendants' Motion for Summary Judgment (Jan. 18, 2005).
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Ortho-McNeil Pharmaceutical, Inc., v. Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA, Inc., Deposition of Paul Short (Nov. 22 2004).
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Ortho-McNeil Pharmaceutical, Inc., v. Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA, Inc., Deposition of Robert W. Croce (Nov. 22, 2004).
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Ortho-McNeil Pharmaceutical, Inc., v. Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA, Inc., Expert Report of David Schoenfeld, Ph.D. (Mar. 31, 2005).
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Ortho-McNeil Pharmaceutical, Inc., v. Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA, Inc., Expert Report of Donald R. Stanski, M.D.(Jan. 14, 2005), [Redacted].
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Ortho-McNeil Pharmaceutical, Inc., v. Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA, Inc., Expert Report of Eric Smith, Ph.D. (Jan. 14, 2005).
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Ortho-McNeil Pharmaceutical, Inc., v. Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA, Inc., Expert Report of Gilbert J. Fanciullo, M.D., (Mar. 17, 2005).
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Ortho-McNeil Pharmaceutical, Inc., v. Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA, Inc., Plaintiff's Brief in Opposition to Teva's Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Pat. No. 5,336,691: Claim 6 (Feb. 17, 2005) [Redacted].
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Ortho-McNeil Pharmaceutical, Inc., v. Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA, Inc., Plaintiff's Rule 56.1 Statement of Disputed Material Facts in Opposition to Defendants Teva Ltc. And Teva USA's Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Pat. No. 5,336,691: Claim 6 Feb. 17, 2005.
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Ortho-McNeil Pharmaceutical, Inc., v. Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA, Inc., Reply Brief in Further Support of Defendants' Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Pat. No. 5,336,691 Claim 6, Mar. 15, 2005 (Redacted).
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Ortho-McNeil Pharmaceutical, Inc., v. Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals USA, Inc.'s Responses and Objections to Plaintiff Ortho-McNeil Pharmaceutical, Inc.'s First Set of Interrogatories [Redacted].
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Ortho-McNeil Pharmaceutical, Inc., v. Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals USA, Inc.'s Supplemental Responses and Objections to Plaintiff Ortho-McNeil Pharmaceutical, Inc.'s First Set of Interrogatories, Dec. 10, 2004.
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Ortho-McNeil Pharmaceutical, Inc., v. Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA, Inc., Teva Pharmaceuticals USA, Inc.'s Supplemental Responses and Objections to Plaintiff Ortho-McNeil Pharmaceutical, Inc.'s First Set of Interrogatories, Nov. 29, 2004.
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Ortho-McNeil Pharmaceutical, Inc., v. Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals, USA, Inc., Complaint, (Feb. 25, 2004).
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Ortho-McNeil Pharmaceutical, Inc., v. Teva Pharmaceutical Industries Ltd., Deposition of Donald Stanski, M.D., May 27, 2005 (REDACTED).
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Ortho-McNeil Pharmaceutical, Inc., v. Teva Pharmaceutical Industries Ltd., Deposition of Dr. David Schoenfeld, May 17, 2005.
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Ortho-McNeil Pharmaceutical, Inc., v. Teva Pharmaceutical Industries Ltd., Deposition of Dr. Gilbert Fanciullo, Jun. 14, 2005.
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Ortho-McNeil Pharmaceutical, Inc., v. Teva Pharmaceutical Industries Ltd., Videotape Deposition of Eric Smith, Ph.D., May 13, 2005.
In the United States District Court for the District of New Jersey, Civil Action No. 04-886(HAA), Teva Pharmaceutical Industries LTD.'s Answer, Affirmative Defenses, Counterclaims and Demand for Jury Trail (Mar. 19, 2004), Teva Pharmaceuticals USA, Inc.'s Answer, Affirmative Defenses, and Counterclaims.
In the United States District Court for the District of New Jersey, Civil Action No:. 04-886(HAA), Teva Pharmaceutical Industries Ltd.'s Amended Answer, Affirmative Defenses, Counterclaims and Demand for Jury Trial (Oct. 26, 2004), Teva Pharmaceutical USA, Inc.'s Amended Answer, Affirmative Defenses, Counterclaims and Demand for Jury Trial (Oct. 26, 2004).
In the United States District Court for the Eastern District of Michigan, Civil Action No. 2:04CV73698, Ortho-McNeil Pharmaceutical, Inc., v. Caraco Pharmaceutical Laboratories, Ltd., Caraco's Motion for Summary Judgment of Non-Infringement, Aug. 5, 2005, REDACTED.
In the United States District Court for the Eastern District of Michigan, Civil Action No. 2:04CV73698, Ortho-McNeil Pharmaceutical, Inc., v. Caraco Pharmaceutical Laboratories, Ltd., Caraco's Second Supplemental Response to Plaintiff's First Set of Interrogatories, Jun. 24, 2005.
In the United States District Court for the Eastern District of Michigan, Civil Action No. 2:04CV73698, Ortho-McNeil Pharmaceutical, Inc., v. Caraco Pharmaceutical Laboratories, Ltd., Caraco's Supplemental Response to Plaintiff's First Set of Interrogatories, Jun. 14, 2005, REDACTED.
In the United States District Court for the Eastern District of Michigan, Civil Action No. 2:04CV73698, Ortho-McNeil Pharmaceutical, Inc., v. Caraco Pharmaceutical Laboratories, Ltd., Expert Report of Donald R. Stanski, M.D. Aug. 5, 2005, REDACTED.
In the United States District Court for the Eastern District of Michigan, Civil Action No. 2:04CV73698, Ortho-McNeil Pharmaceutical, Inc., v. Caraco Pharmaceutical Laboratories, Ltd., Expert Report of Eric P. Smith, Ph.D., Aug. 8, 2005.
In the United States District Court for the Eastern District of Michigan, Civil Action No. 2:04CV73698, Ortho-McNeil Pharmaceutical, Inc., v. Caraco Pharmaceutical Laboratories, Ltd., Ortho-McNeil's Opposition to Caraco's Motion for Summary Judgment of Non-Infringement, Aug. 29, 2005, REDACTED.
Goldberg et al. 1968 An investigation of the structural requirements for dopamine-like renal vasodilation: phenylethylamines and apomorphine
Brinkmann et al. 2001 FTY720: altered lymphocyte traffic results in allograft protection
JP4343948B2 (en) 2009-10-14 Compositions for affecting weight loss
CA2126305C (en) 2006-10-17 New treatments using venlafaxine
EP1539166B1 (en) 2008-07-02 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US8269040B2 (en) 2012-09-18 Derivatives of venlafaxine and methods of preparing and using the same
EP2081571B1 (en) 2010-08-25 MIXED ORL 1/µ AGONISTS FOR TREATING PAIN
EP0103636B1 (en) 1990-09-12 Use of opium antagonists for the manufacture of medicaments for controlling gastrointestinal dysmotility
EP1753414B1 (en) 2011-12-28 Novel use of peptide compounds for treating dyskinesia
US9593070B2 (en) 2017-03-14 Exo-S-mecamylamine formulation and use in treatment
ES2234651T3 (en) 2005-07-01 Composition comprising a tramadol material and an anticonvulsant drug.
JP2007210995A (en) 2007-08-23 Pharmaceutical composition containing opiate antagonist and calcium salt and their use for treatment of endorphin-mediated pathology
Owner name: ORTHO-MCNEIL PHARAMACEUTICAL, INC., NEW JERSEY
Free format text: MERGER;ASSIGNORS:ORTHO PHARMACUETICAL CORPORATION;MCNEILAB, INC.;REEL/FRAME:017507/0355
Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE FIRST ASSIGNOR;ASSIGNORS:ORTHO PHARMACEUTICAL CORPORATION;MCNEILAB, INC.;REEL/FRAME:017507/0655
Owner name: ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC., NEW JE
Free format text: AGREEMENT FOR TRANSFER OF ASSETS AND BILL OF SALE;ASSIGNOR:ORTHO-MCNEIL PHARMACEUTICAL, INC.;REEL/FRAME:021478/0158